Literature DB >> 27575581

Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients.

Massimiliano Fabbiani1, Simona Di Giambenedetto2, Andrea Poli3, Alberto Borghetti4, Antonella Castagna3, Annalisa Mondi4, Nadia Galizzi3, Myriam Maillard5, Andrea Gori6, Roberto Cauda4, Andrea De Luca7, Nicola Gianotti5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27575581     DOI： 10.1016/j.jinf.2016.08.011

Source DB:  PubMed          Journal:  J Infect        ISSN： 0163-4453            Impact factor:   6.072


× No keyword cloud information.
  2 in total

1.  Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015.

Authors:  Eugenia Quiros-Roldan; Paola Magro; Elena Raffetti; Ilaria Izzo; Alessandro Borghetti; Francesca Lombardi; Annalisa Saracino; Franco Maggiolo; Francesco Castelli
Journal:  BMC Infect Dis       Date:  2018-06-25       Impact factor: 3.090

2.  Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.

Authors:  Barbara Rossetti; Roberta Gagliardini; Genny Meini; Gaetana Sterrantino; Vincenzo Colangeli; Maria Carla Re; Alessandra Latini; Manuela Colafigli; Francesca Vignale; Stefano Rusconi; Valeria Micheli; Antonio Di Biagio; Giancarlo Orofino; Valeria Ghisetti; Alessandra Fantauzzi; Vincenzo Vullo; Pierfrancesco Grima; Daniela Francisci; Claudio Mastroianni; Andrea Antinori; Michele Trezzi; Lucia Lisi; Pierluigi Navarra; Benedetta Canovari; Antonella D'Arminio Monforte; Silvia Lamonica; Alessandro D'Avino; Maurizio Zazzi; Simona Di Giambenedetto; Andrea De Luca
Journal:  PLoS One       Date:  2017-11-21       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.